Detail akcie VRAX Rg online

Business Summary: Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The Company is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).
Financial Summary: BRIEF: For the six months ended 30 September 2025, Virax Biolabs Group Ltd revenues decreased 68% to $2K. Net loss decreased 15% to $2.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Biotechnology & Medical Research segment loss decrease of 10% to $2.6M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.89 to -$0.49.